A double-blind placebo-controlled study of fluvoxamine and imipramine in depression

R. A. Dominguez, B. J. Goldstein, A. F. Jacobson, R. M. Steinbook

Research output: Contribution to journalArticlepeer-review

62 Scopus citations


Outpatients with major affective disorder, unipolar depressed type (N = 101), were treated in a 4-week placebo-controlled double-blind study, to compare the efficacy and safety of fluvoxamine, a new serotonin reuptake inhibitor antidepressant, with imipramine and placebo. Therapy was initiated at 50 mg/day; thereafter, dosage ranged between 100 and 300 mg/day for both drugs. Results indicate statistically significant efficacy, measured by both patient and physician rating scales, for both active drugs over placebo. Fluvoxamine showed some evidence of earlier onset of action. Anticholinergic side effects were more common in the imipramine-treated patients, while fluvoxamine produced more gastrointestinal distress and insomnia.

Original languageEnglish (US)
Pages (from-to)84-87
Number of pages4
JournalJournal of Clinical Psychiatry
Issue number3 I
StatePublished - Jan 1 1985

ASJC Scopus subject areas

  • Psychiatry and Mental health


Dive into the research topics of 'A double-blind placebo-controlled study of fluvoxamine and imipramine in depression'. Together they form a unique fingerprint.

Cite this